Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14879537 | 1.00 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL14879526 | 0.92 | ARG1 (1.00) | ARG1ARG2 | |
| SCHEMBL895368 | 0.92 | ARG1 (1.00) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL893814 | 0.90 | ARG1 (0.97) | ARG1ARG2 | |
| SCHEMBL10006356 | 0.86 | ARG1 (0.89) | ARG1ARG2 | |
| SCHEMBL894819 | 0.83 | ARG1 (0.80) | ARG1ARG2 | |
| SCHEMBL18323826 | 0.83 | ARG1 (0.71) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895271 | 0.82 | ARG1 (0.78) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL895774 | 0.81 | ARG1 (0.76) | ARG1ARG2 | |
| Hydrochloric Acid SCHEMBL28034066 | 0.81 | ARG1 (0.70) | ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-2768491-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9266908-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-11-20 | — | — | US | disclosed |
| EP-2768491-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013059437-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343019-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT1 | ARG1 1/4885ARG2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.